Alclofenac
Based on 1 Customer Validation
Alclofenac (Allopydin) is an orally active prostaglandin synthase inhibitor with anti-inflammatory, analgesic and antipyretic activities. Alclofenac irreversibly inhibits platelet aggregation. Alclofenac can be used in research related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, low back pain and sciatica.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.44%
- CAS. Nr.: 22131-79-9
- Formel: C11H11ClO3
- Molecular Weight:226.66
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Alclofenac inhibits prostaglandin biosynthesis in vitro in ram seminal vesicle microsomes[1].
Alclofenac inhibits oxidative phosphorylation in rat liver mitochondria in vitro[1].
Alclofenac exerts cytostatic and cytotoxic effects on mammalian cells in vitro[1].
Alclofenac inhibits collagen- or epinephrine-induced human platelet aggregation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Alclofenac (25-100 mg/kg; p.o./s.c.) prevents and treats adjuvant-induced arthritis in rats[1].
Alclofenac exhibits analgesic activity in rats[1].
Alclofenac (100-200 mg/kg; p.o.) exerts a dose-dependent antipyretic effect in febrile rabbits[1].
Alclofenac (100-200 mg/kg; p.o./i.p.) exerts central nervous system depressant activity in rats, which is manifested by prolonged pentobarbital-induced sleep time[1].
Alclofenac (10-960 mg/kg; p.o.; once daily; for 5 consecutive days) inhibits acute inflammation in rats in a dose-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Carrageenin-induced paw oedema in rats[1]
-
Dosage:20 mg/kg (p.o.); 40 mg/kg (p.o.); 80 mg/kg (p.o.); 25 mg/kg (s.c.); 100 mg/kg (s.c.)
-
Administration:p.o.; s.c.
-
Result:Slightly, but not significantly, suppressed carrageenin-induced paw oedema more effectively than equal doses of Phenylbutazone (HY-B0230) at oral doses of 20, 40, and 80 mg/kg.
Showed activity not significantly different from equal doses of Phenylbutazone at subcutaneous doses of 25 and 100 mg/kg.
Demonstrated effect independent of intact adrenals.
Chemical Information
-
CAS. Nr. 22131-79-9
-
Appearance Solid
-
Molecular Weight 226.66
-
Formel C11H11ClO3
-
Color White to off-white
-
SMILES
C=CCOC1=C(Cl)C=C(CC(O)=O)C=C1
-
Synonyms
Allopydin; W-7320
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 16.67 mg/mL (73.55 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (7.37 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (7.37 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Brogden RN, et al. Alclofenac: a review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders. Drugs. 1977;14(4):241-259. [Content Brief]
[2]. Woodland J, et al. Comparison of the effects of alclofenac, flurbiprofen, and prednisolone on acute inflammatory response in the rat. Ann Rheum Dis. 1977;36(2):160-165. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.4119 mL | 22.0595 mL | 44.1189 mL | 110.2974 mL |
| 5 mM | 0.8824 mL | 4.4119 mL | 8.8238 mL | 22.0595 mL | |
| 10 mM | 0.4412 mL | 2.2059 mL | 4.4119 mL | 11.0297 mL | |
| 15 mM | 0.2941 mL | 1.4706 mL | 2.9413 mL | 7.3532 mL | |
| 20 mM | 0.2206 mL | 1.1030 mL | 2.2059 mL | 5.5149 mL | |
| 25 mM | 0.1765 mL | 0.8824 mL | 1.7648 mL | 4.4119 mL | |
| 30 mM | 0.1471 mL | 0.7353 mL | 1.4706 mL | 3.6766 mL | |
| 40 mM | 0.1103 mL | 0.5515 mL | 1.1030 mL | 2.7574 mL | |
| 50 mM | 0.0882 mL | 0.4412 mL | 0.8824 mL | 2.2059 mL | |
| 60 mM | 0.0735 mL | 0.3677 mL | 0.7353 mL | 1.8383 mL |
Alclofenac Related Classifications
HY-W009706 Related Classifications
Powered by Bioz
- Alclofenac
- 22131-79-9
- Allopydin
- W-7320
- W7320
- W 7320
- W-7320
- Prostaglandin Receptor
- prostaglandin synthase
- human platelet aggregation
- carrageenin-induced paw oedema
- rheumatoid arthritis
- human serum albumin
- rat liver mitochondria
- adjuvant-induced polyarthritis
- sheep seminal vesicle microsomes
- mammalian cells
- L-tryptophan
- Inhibitor
- inhibitor
- inhibit